论文部分内容阅读
1989年Skobelott等对38例吸入舒喘宁(al- buterol)无效的中度到重度的哮喘病人,用随机双盲的方法静脉注射1.2g镁,结果住院率明显降低,最大呼气流速也显著改善。1990年3月到1991年3月,Green等对(120名年龄在18～65岁,吸氧吸舒喘宁无效的急性哮喘病人进行了前瞻性随机临床研究。他们的研究结果否定了Skobelott的结论。58例接受镁治疗的患者有13例(22％)需住院治疗,62例对照组有11例(18％)需住院治疗,P=0.523,没有显著差异,病人在急诊科治疗时间,镁治疗组是224±75分,对
In 1989, Skobelott and other 38 patients with moderate to severe asthma who were refractory to al- buterol were intravenously injected with 1.2 g of magnesium using a randomized, double-blind approach, resulting in a significant reduction in hospitalization and a maximum expiratory flow rate improve. From March 1990 to March 1991, Green et al. (Prospectively randomized clinical trial of 120 asthmatic asthmatic patients aged 18-65 years who were not inhaled orally inhaled sulbactam.Their findings negated the use of Skobelott’s Conclusions. Fifty-eight patients receiving magnesium therapy required hospitalization in 13 (22%) patients and 11 (18%) in 62 patients in the control group requiring hospitalization (P = 0.523). There was no significant difference in the duration of emergency treatment, The magnesium treatment group was 224 ± 75 minutes, yes